Developer of small molecule therapeutics designed to provide treatment for lysosomal storage disorders. The company's therapeutics aim to boost lysosome biogenesis via PPA-dependent upregulation, enabling patients suffering from lysosomal storage and neurodegenerative disorders to have orally available small molecule therapeutics.
linkedin.comPart of: Top Startups in New Jersey